Current clinical guidelines recommend SGLT2 inhibitors for patients with heart failure or kidney disease, while GLP-1 receptor agonists are advised for individuals with type 2 diabetes at high risk of atherosclerotic CVD or stroke, as well as for those with kidney disease [159]. The gene discussed is SLC5A2; the disease is kidney disorder.